This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.
Age from 18 to 75 years
Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically
CT/MRI, PET-CT, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of distant metastasis
Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
History of other malignant disease within past five years
History of immunodeficiency, including HIV positive, or other acquired congenital immunodeficiency disease, or a history of organ transplantation and allogeneic bone marrow transplantation
Accompanied by serious heart, lung, liver and kidney diseases, neuropsychiatric disorders, jaundice or associated severe infection
Women during pregnancy or breast-feeding
Parallel
Palliative surgery after translational therapy
Combination productA total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy . location.
Chemotheraoy along
DrugPatients receive only the prescribed chemotherapy.
2-year overall survival rate
Survival rate of patients in the group from the date of enrollment to 2 years after enrollment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
